{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Therriault J"],"funding":["Weston Brain Institute","NIA NIH HHS","UK Dementia Research Institute","Alzheimer&apos;s Association","Alzheimer's Association"],"pagination":["4967-4977"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10587362"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["19(11)"],"pubmed_abstract":["<h4>Introduction</h4>Plasma biomarkers are promising tools for Alzheimer's disease (AD) diagnosis, but comparisons with more established biomarkers are needed.<h4>Methods</h4>We assessed the diagnostic performance of p-tau<sub>181</sub> , p-tau<sub>217</sub> , and p-tau<sub>231</sub> in plasma and CSF in 174 individuals evaluated by dementia specialists and assessed with amyloid-PET and tau-PET. Receiver operating characteristic (ROC) analyses assessed the performance of plasma and CSF biomarkers to identify amyloid-PET and tau-PET positivity.<h4>Results</h4>Plasma p-tau biomarkers had lower dynamic ranges and effect sizes compared to CSF p-tau. Plasma p-tau<sub>181</sub> (AUC = 76%) and p-tau<sub>231</sub> (AUC = 82%) assessments performed inferior to CSF p-tau<sub>181</sub> (AUC = 87%) a"],"journal":["Alzheimer's & dementia : the journal of the Alzheimer's Association"],"pubmed_title":["Equivalence of plasma p-tau217 with cerebrospinal fluid in the diagnosis of Alzheimer's disease."],"pmcid":["PMC10587362"],"funding_grant_id":["SG-23-1038904 QC","NIRP‐12‐259245","R01 AG068398","UKDRI‐1003","NIRG‐12‐92090","NIRP-12-259245","R01 AG083874","SG‐23‐1038904 QC","NIRG-12-92090"],"pubmed_authors":["Gauthier S","Stevenson J","Haeger A","Nazneen T","Zetterberg H","Aumont E","Pascoal TA","Rej S","Benedet AL","Therriault J","Kolb HC","Rahmouni N","Vitali P","Servaes S","Rosa-Neto P","Triana-Baltzer G","Socualaya KQ","Tissot C","Ashton NJ","Soucy JP","Stevenson A","Fernandez-Arias J","Wang YT","Hosseini A","Macedo AC","Karikari TK","Blennow K","Lussier FZ"],"additional_accession":[]},"is_claimable":false,"name":"Equivalence of plasma p-tau217 with cerebrospinal fluid in the diagnosis of Alzheimer's disease.","description":"<h4>Introduction</h4>Plasma biomarkers are promising tools for Alzheimer's disease (AD) diagnosis, but comparisons with more established biomarkers are needed.<h4>Methods</h4>We assessed the diagnostic performance of p-tau<sub>181</sub> , p-tau<sub>217</sub> , and p-tau<sub>231</sub> in plasma and CSF in 174 individuals evaluated by dementia specialists and assessed with amyloid-PET and tau-PET. Receiver operating characteristic (ROC) analyses assessed the performance of plasma and CSF biomarkers to identify amyloid-PET and tau-PET positivity.<h4>Results</h4>Plasma p-tau biomarkers had lower dynamic ranges and effect sizes compared to CSF p-tau. Plasma p-tau<sub>181</sub> (AUC = 76%) and p-tau<sub>231</sub> (AUC = 82%) assessments performed inferior to CSF p-tau<sub>181</sub> (AUC = 87%) a","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Nov","modification":"2025-04-19T18:13:45.529Z","creation":"2025-04-19T18:13:45.529Z"},"accession":"S-EPMC10587362","cross_references":{"pubmed":["37078495"],"doi":["10.1002/alz.13026"]}}